Market Reports Center One Stop Market Reaserch Shop Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Global Clinical Trials Review, H1, 2016 Summary GlobalData's clinical trial report, “Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Global Clinical Trials Review, H1, 2016" provides an overview of Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) clinical trials scenario. This report provides top line data relating to the clinical trials on Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’ s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. Browse full report with TOC@ https://marketreportscenter.com/reports/327218/chronic-myelocyticleukemia-cml-chronic-myeloid-leukemia-global-clinical-trials-review-h1-2016 The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage. *Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Market Reports Center One Stop Market Reaserch Shop Scope - The report provides a snapshot of the global clinical trials landscape - Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status - The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company - The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment - The Report provides enrollment trends for the past five years - Report provides latest news for the past three months *Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Reasons to buy - Assists in formulating key business strategies with regards to investment - Helps in identifying prominent locations for conducting clinical trials which saves time and cost - Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities - Supports understanding of trials count and enrollment trends by country in global therapeutics market - Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials - Facilitates clinical trial assessment of the indication on a global, regional and country level *Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Request A Sample copy of This Report @ https://marketreportscenter.com/request-sample/327218 Table Of Content Table of Contents Table of Contents 2 List of Tables 3 List of Figures 4 Report Guidance 5 Clinical Trials by Region 6 Clinical Trials and Average Enrollment by Country 7 Top Five Countries Contributing to Clinical Trials in Asia-Pacific 9 Top Five Countries Contributing to Clinical Trials in Europe 10 Market Reports Center One Stop Market Reaserch Shop Top Countries Contributing to Clinical Trials in North America 11 Top Five Countries Contributing to Clinical Trials in Middle East and Africa 12 Top Five Countries Contributing to Clinical Trials in Central and South America 13 Clinical Trials by G7 Countries: Proportion of Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) to Oncology Clinical Trials 14 Clinical Trials by Phase in G7 Countries 15 Clinical Trials in G7 Countries by Trial Status 16 Clinical Trials by E7 Countries: Proportion of Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) to Oncology Clinical Trials 17 Clinical Trials by Phase in E7 Countries 18 Clinical Trials in E7 Countries by Trial Status 19 Clinical Trials by Phase 20 In Progress Trials by Phase 21 Clinical Trials by Trial Status 22 Clinical Trials by End Point Status 23 Subjects Recruited Over a Period of Time 24 Clinical Trials by Sponsor Type 25 Prominent Sponsors 26 Top Companies Participating in Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Therapeutics Clinical Trials 27 Prominent Drugs 28 Latest Clinical Trials News on Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) 29 Jun 09, 2016: Bristol-Myers Squibb to Present Data on Sprycel (dasatinib) at the 21st Congress of the European Hematology Association 29 Jun 06, 2016: Bio-Path Holdings Reports Promising Data from Phase I and Phase II Clinical Trials of BP1001 in Blood Cancers Presented at ASCO 2016 29 Jun 04, 2016: Novartis data show more than 50 percent of eligible Ph+ CML patients maintain Treatment-free Remission after stopping Tasigna 30 May 18, 2016: ARIAD to present ponatinib hydrochloride data at the 2016 ASCO Annual Meeting 31 Apr 20, 2016: Preclinical Data Presented At AACR Indicate Pacritinib Potential To Eradicate TherapyResistant Leukemia Stem Cells Residing In Bone Marrow Microenvironment 31 Clinical Trial Profile Snapshots 33 Appendix 1126 Abbreviations 1126 Definitions 1126 Research Methodology 1127 Secondary Research 1127 About GlobalData 1128 Contact Us 1128 Disclaimer 1128 Source 1129 To Get Discount On The Report @ https://marketreportscenter.com/request-discount/327218 Market Reports Center One Stop Market Reaserch Shop Connect for more details: Sam Collins Market Reports Center 1-646-883-3044 (US) info@marketreportscenter.com
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
© Copyright 2024 Paperzz
